Asian Stock Picks Estimated To Be Trading Below Fair Value For August 2026

As of August 2026, Asian markets have shown mixed performance, with some regions experiencing growth driven by technological advancements and others facing challenges from geopolitical tensions and regulatory changes. In such an environment, identifying undervalued stocks requires a keen understanding of market dynamics and the ability to recognize companies that are trading below their intrinsic value.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Click here to see the full list of 216 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Yunnan Shennong Agricultural Industry Group (SHSE:605296)

Overview: Yunnan Shennong Agricultural Industry Group Co., Ltd. operates in the livestock business both in China and internationally, with a market cap of CN¥16.36 billion.

Operations: The company generates revenue from its livestock operations in both domestic and international markets.

Estimated Discount To Fair Value: 6.6%

Yunnan Shennong Agricultural Industry Group is trading at CN¥31.57, slightly below its estimated future cash flow value of CN¥33.8, suggesting it is undervalued based on cash flows. Revenue growth is expected to outpace the market significantly at 26% annually, and earnings are projected to grow very rapidly each year. However, the dividend yield of 2.47% isn't well covered by free cash flows, and return on equity remains low forecasted at 16.2%.

• According our earnings growth report, there's an indication that Yunnan Shennong Agricultural Industry Group might be ready to expand.
• Click here to discover the nuances of Yunnan Shennong Agricultural Industry Group with our detailed financial health report.

Sino Medical Sciences Technology (SHSE:688108)

Overview: Sino Medical Sciences Technology Inc. is a medical device company focused on the research, development, production, and distribution of interventional medical devices in China with a market cap of CN¥7.80 billion.

Operations: The company's revenue primarily comes from its Medical Products segment, which generated CN¥564.29 million.

Estimated Discount To Fair Value: 29.9%

Sino Medical Sciences Technology is trading at CN¥18.66, well below its estimated future cash flow value of CN¥26.62, indicating undervaluation based on cash flows. Revenue growth is forecast at 19.6% annually, outpacing the Chinese market's 16.5%, while earnings are expected to grow significantly at 27.94% per year, surpassing market averages. Despite recent share buybacks totaling CN¥19.93 million, the stock remains highly volatile with a low projected return on equity of 10%.

• Our earnings growth report unveils the potential for significant increases in Sino Medical Sciences Technology's future results.
• Navigate through the intricacies of Sino Medical Sciences Technology with our comprehensive financial health report here.

WNC (TWSE:6285)

Overview: WNC Corporation, along with its subsidiaries, is involved in the research, development, manufacture, and sale of satellite, mobile, and portable communication equipment across the Americas, Asia, Europe, and internationally with a market cap of approximately NT$123.82 billion.

Operations: The company's revenue primarily comes from its Wireless Communications Equipment segment, which generated NT$122.99 billion.

Estimated Discount To Fair Value: 33.9%

WNC Corporation is trading at NT$256, below its estimated future cash flow value of NT$387.23, suggesting undervaluation based on cash flows. Earnings are projected to grow significantly at 30.5% annually, outpacing the Taiwanese market's 26%. Despite high earnings growth and a strong recent performance with net income rising to TWD 1,629.58 million for Q2 2026 from TWD 493.17 million a year ago, the dividend yield of 1.68% is not well covered by free cash flows and share price volatility remains high.

• Our growth report here indicates WNC may be poised for an improving outlook.
• Delve into the full analysis health report here for a deeper understanding of WNC.

Make It Happen

• Click this link to deep-dive into the 216 companies within our Undervalued Asian Stocks Based On Cash Flows screener.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com